Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: ProSanos and Management Science Associates Forge Alliance

This story has been updated from a previous version.

NEW YORK, June 21 – ProSanos and Management Science Associates have entered into a strategic relationship to develop and market biomedical informatics, the companies said Thursday. 

As part of the collaboration, MSA took an equity stake in ProSanos, Jonathan Morris, CEO of ProSanos, told GenomeWeb. Further financial details of the agreement were not disclosed. 

As a first step in this alliance, the companies have already built a joint data center to address security issues and biomedical data integrity standards. 

“MSA has a proven track record, not only with infrastructure but also with domain and security expertise that complements us,” said Morris. “They have all of the physical plant where we can host our high performance needs."

La Jolla, Calif.-based ProSanos, formerly called GenMatics, incorporates clinical outcomes information with molecular data in disease models. Management Science Associates of Pittsburgh, through its medical division, develops analytical software and data management to collect, annotate, analyze, and store clinical and molecular data.

Morris declined to offer additional information about his company.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.